 Purpura, Thrombocytopenic, Idiopathic
"Purpura, Thrombocytopenic, Idiopathic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
| Descriptor ID |
D016553
|
| MeSH Number(s) |
C15.378.100.802.687.600 C15.378.140.855.925.750.600 C15.378.463.740 C20.111.759 C20.841.600 C23.550.414.950.687.600 C23.888.885.687.687.600
|
| Concept/Terms |
Purpura, Thrombocytopenic, Idiopathic- Purpura, Thrombocytopenic, Idiopathic
- Idiopathic Thrombocytopenic Purpura
- Idiopathic Thrombocytopenic Purpuras
- Purpura, Idiopathic Thrombocytopenic
- Purpuras, Idiopathic Thrombocytopenic
- Thrombocytopenic Purpura, Idiopathic
- Thrombocytopenic Purpuras, Idiopathic
- Werlhof's Disease
- Disease, Werlhof's
- Werlhofs Disease
- Purpura, Thrombocytopenic, Autoimmune
- Thrombocytopenic Purpura, Autoimmune
- Werlhof Disease
- Disease, Werlhof
- Autoimmune Thrombocytopenic Purpura
- Autoimmune Thrombocytopenic Purpuras
- Purpura, Autoimmune Thrombocytopenic
- Purpuras, Autoimmune Thrombocytopenic
- Immune Thrombocytopenic Purpura
Autoimmune Thrombocytopenia- Autoimmune Thrombocytopenia
- Autoimmune Thrombocytopenias
- Thrombocytopenia, Autoimmune
- Thrombocytopenias, Autoimmune
|
Below are MeSH descriptors whose meaning is more general than "Purpura, Thrombocytopenic, Idiopathic".
- Diseases [C]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Blood Coagulation Disorders [C15.378.100]
- Purpura [C15.378.100.802]
- Purpura, Thrombocytopenic [C15.378.100.802.687]
- Purpura, Thrombocytopenic, Idiopathic [C15.378.100.802.687.600]
- Blood Platelet Disorders [C15.378.140]
- Thrombocytopenia [C15.378.140.855]
- Thrombotic Microangiopathies [C15.378.140.855.925]
- Purpura, Thrombocytopenic [C15.378.140.855.925.750]
- Purpura, Thrombocytopenic, Idiopathic [C15.378.140.855.925.750.600]
- Hemorrhagic Disorders [C15.378.463]
- Purpura, Thrombocytopenic, Idiopathic [C15.378.463.740]
- Immune System Diseases [C20]
- Autoimmune Diseases [C20.111]
- Purpura, Thrombocytopenic, Idiopathic [C20.111.759]
- Purpura, Thrombocytopenic [C20.841]
- Purpura, Thrombocytopenic, Idiopathic [C20.841.600]
- Pathological Conditions, Signs and Symptoms [C23]
- Pathologic Processes [C23.550]
- Hemorrhage [C23.550.414]
- Purpura [C23.550.414.950]
- Purpura, Thrombocytopenic [C23.550.414.950.687]
- Purpura, Thrombocytopenic, Idiopathic [C23.550.414.950.687.600]
- Signs and Symptoms [C23.888]
- Skin Manifestations [C23.888.885]
- Purpura [C23.888.885.687]
- Purpura, Thrombocytopenic [C23.888.885.687.687]
- Purpura, Thrombocytopenic, Idiopathic [C23.888.885.687.687.600]
Below are MeSH descriptors whose meaning is more specific than "Purpura, Thrombocytopenic, Idiopathic".
This graph shows the total number of publications written about "Purpura, Thrombocytopenic, Idiopathic" by people in UAMS Profiles by year, and whether "Purpura, Thrombocytopenic, Idiopathic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2022 | 3 | 0 | 3 | | 2021 | 1 | 0 | 1 | | 2020 | 3 | 0 | 3 | | 2019 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2017 | 2 | 0 | 2 | | 2016 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Purpura, Thrombocytopenic, Idiopathic" by people in Profiles over the past ten years.
-
Nakano TA, Grimes AB, Klaassen RJ, Lambert MP, Neunert C, Rothman JA, Shimano KA, Amend C, Askew M, Badawy SM, Baker JM, Breakey V, Crary S, Davini M, Fritch Lilla S, Gilbert M, Hays T, Hege K, Hillier K, Jacobson-Kelly A, Kaicker S, Kim TO, Kochhar M, Leblanc T, Martinelli M, Nunez M, Remiker A, Schultz C, Sharma R, Grace RF. What is in a name: defining pediatric refractory ITP. Blood Adv. 2024 10 08; 8(19):5112-5117.
-
Saluja P, Gautam N, Yadala S, Venkata AN. Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases. Thromb Res. 2022 06; 214:115-121.
-
Calcaterra G, Bassareo PP, Barilla' F, Romeo F, Mehta JL. Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown). 2022 02 01; 23(2):71-74.
-
Calcaterra G, Bassareo PP, De Gregorio C, Barilla F, Romeo F, Mehta JL. COVID-19 Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia (VIPIT): State of the Art. Curr Cardiol Rev. 2022; 18(5):11-17.
-
Aroshidze B, Nalghranyan S, Gotlieb G, Erdinc B, Aggarwal A, El Younis C, Avezbakiyav B. Treatment-Refractory, Primary Immune Thrombocytopenic Purpura in a Patient with Celiac Disease. Am J Case Rep. 2021 Oct 10; 22:e931877.
-
Roy AM, Konda M, Sidarous GK, Atwal D, Schichman SA, Kunthur A. Acquired Amegakaryocytic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia: A Case Report. Perm J. 2020 12; 24:1-3.
-
Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Clin Ther. 2020 05; 42(5):860-872.e8.
-
Forsythe A, Schneider J, Pham T, Bhor M, Said Q, Allepuz A, Socorro O Portella MD, Kwon CS, Roy AN. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. J Comp Eff Res. 2020 05; 9(7):447-457.
-
Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol. 2019 07; 94(7):741-750.
-
Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. Am J Hematol. 2018 07; 93(7):882-888.
-
Quach ME, Dragovich MA, Chen W, Syed AK, Cao W, Liang X, Deng W, De Meyer SF, Zhu G, Peng J, Ni H, Bennett CM, Hou M, Ware J, Deckmyn H, Zhang XF, Li R. Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. Blood. 2018 02 15; 131(7):787-796.
-
Com G, Awad S, Trenor CC. Delayed Appearance of Cutaneous Lesions of Cutaneovisceral Angiomatosis (CAT) Leading to Misdiagnosis of Immune Thrombocytopenia. J Pediatr Hematol Oncol. 2017 05; 39(4):e236-e239.
-
Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 08; 63(8):1407-13.
-
Jern?s M, Str?mberg C?lind F, Nookaew I, Mellgren K, Wadenvik H, Olsson B. Normalised immune expression in remission of paediatric ITP. Thromb Haemost. 2016 06 02; 115(6):1229-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|